Bcd-089    (DrugBank: -)

1 disease
IDDisease name (Link within this page)Number of trials
46Malignant rheumatoid arthritis2

46. Malignant rheumatoid arthritis    [ 4,183 clinical trials,   2,538 drugs,   (DrugBank: 401 drugs),   183 drug target genes,   219 drug target pathways]
Searched query = "Malignant rheumatoid arthritis", "Rheumatoid arthritis", "Rheumatoid arthritis with vasculitis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
2 / 4,183 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT04227366
(ClinicalTrials.gov)
November 19, 201925/12/2019Study of the Efficacy and Safety of BCD-089 in Combination With Methotrexate in Patients With Active Rheumatoid ArthritisAn International, Multicenter, Randomized, Double-blind, Placebo-controlled Clinical Study of the Efficacy and Safety of BCD-089 (JSC BIOCAD, Russia) in Combination With Methotrexate in Patients With Active Rheumatoid ArthritisRheumatoid ArthritisBiological: BCD-089;Biological: Placebo;Drug: MethotrexatBiocadNULLActive, not recruiting18 YearsN/AAll150Phase 3Russian Federation
2NCT03455842
(ClinicalTrials.gov)
February 1, 201822/2/2018The BCD-089 (aIL6R) in Patients With Active Rheumatoid ArthritisInternational Multicenter Comparative Randomized Double-blind Placebo-controlled Clinical Study of Efficacy and Safety of BCD-089 in Different Dosing Regimens in Patients With Active Rheumatoid ArthritisSeropositive RABiological: BCD-089, 162 mg, s/c, qw;Biological: BCD-089, 162 mg, s/c, q2w;Drug: placeboBiocadNULLCompleted18 Years80 YearsAll105Phase 2Belarus;Russian Federation